GSK expands into Pakistan
This article was originally published in The Tan Sheet
The U.K. firm gains more than 30 pharmaceutical brands, including antibiotics, vitamins and dermatology products, in its purchase of Bristol-Myers Squibb Pakistan, GlaxoSmithKline announces Dec. 22. The $36.5 million acquisition "reinforces our commitment to Pakistan" and broadens GSK's product portfolio, says Abbas Hussain, president of emerging markets for GSK. The company says BMSP's 2007 sales were about $19 million and Pakistan's total pharmaceutical market is $1.2 billion. GSK's goal is to introduce old products in new places and coordinate its Rx and OTC segments in emerging markets (1"The Tan Sheet" Oct. 27, 2008, p. 14)
You may also be interested in...
GlaxoSmithKline recently launched its Sensodyne toothpaste line in China, its first new product there in more than 10 years
Device Week, 05 March - Remote Monitoring Reimbursement, T-cell Diagnostics And A Digital Health Feature
In this week's podcast, managing editor Marion Webb discusses a new monthly digital health roundup which will soon feature on Medtech Insight. Managing editor Reed Miller discusses reimbursement difficulties as it applies to remote cardiac monitoring. UK-based reporter Barnaby Pickering gives an overview of an interview with the chief medical officer of Adaptive Biotechnologies about its new T-Detect platform.
Coronavirus Notebook: Italy Makes First Use Of EU’s Vaccine Export Control System, More Regulators Issue Guidance On Variants
Ukraine has established a system for issuing emergency use authorizations for COVID-19 vaccines that recognizes authorizations granted by other world regulators.